The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results